Should hepatitis C virus infection be a contraindication to renal transplantation?
Meredith J Aull* and Manikkam Suthanthiran
Correspondence *New York Presbyterian Hospital–Weill Cornell Medical Center, 525 East 68th Street, Box 98, New York, NY 10065, USA
Email mea9008@nyp.org
This article has no abstract so we have provided the first paragraph of the full text.
The standard treatment for HCV infection is pegylated interferon (IFN) plus ribavirin. As a result of impaired renal clearance, patients with chronic kidney disease (CKD)—particularly those on dialysis—experience worse adverse effects from IFN and ribavirin than do those with normal renal function. Patients with CKD are, therefore, often treated with IFN monotherapy, with over one-third achieving a sustained virologic response to this regimen.1 Alternative dosing strategies for ribavirin and pegylated IFN are, however, being studied in patients with CKD.1 Use of IFN after transplantation is generally avoided because it can increase the risk of acute rejection.1
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
